Heart Failure With Preserved Ejection Fraction Clinical Trial
Official title:
GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
Verified date | July 2023 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved ejection fraction (HFpEF)].
Status | Terminated |
Enrollment | 319 |
Est. completion date | June 2, 2023 |
Est. primary completion date | June 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: 1. Medical history of heart failure (HF) with: 1. At least 1 episode with clinical evidence of HF (without hospitalization) by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement; OR 2. 1 prior hospitalization for HF. 2. Left ventricular ejection fraction (LVEF) >40%. 3. End-diastolic interventricular septal wall thickness (IVST) =12 mm. 4. Willing and able to undergo scintigraphy. Exclusion Criteria: 1. Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF =40%). 2. Prior clinical history of myocardial infarction, CABG or multi-vessel obstructive coronary disease (>50% stenosis of =2 epicardial coronary arteries). 3. Presence or history of any severe valvular heart disease (obstructive or regurgitant). 4. A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known pericardial constriction. 5. Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain] amyloidosis) or prior diagnosis of ATTR-CM. - |
Country | Name | City | State |
---|---|---|---|
Canada | University of Ottawa Heart Institute | Ottawa | Ontario |
Canada | CardioVasc HR Inc | Saint-Jean-sur-Richelieu | Quebec |
Canada | Diex Recherche Trois-Rivieres | Trois-Rivieres | Quebec |
France | Hôpital Louis Pradel | Bron Cedex | |
France | Centre Hospitalier Saint-Joseph Saint-Luc | LYON cedex 07 | |
France | CHU Nimes - Hospital Caremeau | Nimes | |
France | CHU de Toulouse - Hôpital de Rangueil | Toulouse cedex 9 | |
France | Médecine Nucléaire de la Doua | Villeurbanne | |
Italy | IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola | Bologna | BO |
Italy | U.O. Clinica delle Malattie dell'Apparato Cardiovascolare - Ospedale Policlinico San Martino IRCCS | Genova | Genoa |
Italy | U.O. Clinica delle Malattie dell'Apparato Cardiovascolare - Ospedale Policlinico San Martino IRCCS | Genova | |
Italy | Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche | Pavia | |
Italy | Fondazione Toscana Gabriele Monasterio-UOC Cardiologia e Medicina Cardiovascolare | Pisa | |
Japan | Fukuoka Tokushukai Hospital | Kasuga | Fukuoka |
Japan | Nagoya Tokushukai General Hospital | Kasugai | Aichi |
Japan | Okayama University Hospital | Okayama | |
Japan | Keio University Hospital | Shinjuku-ku | Tokyo |
Poland | Uniwersytecki Szpital Kliniczny w Bialymstoku | Bialystok | Podlaskie |
Poland | Krakowski Szpital Specjalistyczny im. Jana Pawla II | Krakow | Malopolskie |
Poland | SPZOZ Uniwersytecki Szpital Kliniczny Im. Wojskowej Akademii Medycznej UM W Lodzi Centralny Szpital | Lódz | Lódzkie |
Poland | Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu | Wroclaw | Dolnoslaskie |
Poland | Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu | Wroclaw | Dolnoslaskie |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital Universitari De Bellvitge | Barcelona | |
Spain | Hospital Universitari Vall d´Hebron | Barcelona | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Hospital Universitario Puerta de Hierro Majadahonda | Majadahonda | Madrid |
Spain | Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca | Salamanca | |
Spain | Hospital Universitari i Politècnic La Fe | Valencia | |
United Kingdom | St George's Hospital, St George's University Hospitals NHS Foundation Trust | London | |
United States | Eastern shore Research Institute LLC | Fairhope | Alabama |
United States | Corewell Health | Grand Rapids | Michigan |
United States | Spectrum Health Medical Group Cardiovascular Medicine | Grand Rapids | Michigan |
United States | Chicago Medical Research, LLC | Hazel Crest | Illinois |
United States | Heart Center Research, LLC | Huntsville | Alabama |
United States | The Jackson Clinic | Jackson | Tennessee |
United States | Advance Medical Research Center | Miami | Florida |
United States | Bioclinical Research Alliance Inc. | Miami | Florida |
United States | Biogenix Molecular | Miami | Florida |
United States | CIRA (Nuclear Imaging Facility) | Miami | Florida |
United States | Innova Pharma Research | Miami | Florida |
United States | Nucleotron/ Doral Imaging Institute, CIRA DBA | Miami | Florida |
United States | Ochsner Medical Center | New Orleans | Louisiana |
United States | NYU Langone Health | New York | New York |
United States | Advocate Christ Medical Center | Oak Lawn | Illinois |
United States | Ocala Cardiovascular Research | Ocala | Florida |
United States | WakeMed Health and Hospital | Raleigh | North Carolina |
United States | Providence Sacred Heart Medical Center and Children's Hospital | Spokane | Washington |
United States | Cotton O'Neil Heart Center | Topeka | Kansas |
United States | Stormont Vail Health | Topeka | Kansas |
United States | Cardiology Associates of North Mississippi, LLC | Tupelo | Mississippi |
United States | Cardiology Associates Research, LLC | Tupelo | Mississippi |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Canada, France, Italy, Japan, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimate of global prevalence of ATTR-CM in HFpEF patients. | Includes participants not previously diagnosed with ATTR-CM but found to be positive by scintigraphy at Visit 1 (or subsequent biopsy if grade 1). | Visit 1(baseline) through Follow-Up Visit 1 (Day 44) | |
Secondary | Estimate of prevalence of ATTR-CM within region, age and gender | Includes participants not previously diagnosed with ATTR-CM but found to be positive by scintigraphy at Visit 1 (or subsequent biopsy if grade 1). | Visit 1(baseline) through Follow-Up Visit 1 (Day 44) | |
Secondary | Prevalence of patients diagnosed ATTR-CM on study with WT and hereditary forms among patients diagnosed with ATTR CM | Visit 1(baseline) through Follow-Up Visit 1 (Day 44) | ||
Secondary | New York Heart Association (NYHA) Classification of HFpEF participants diagnosed with ATTR-CM compared with HFpEF participants negative for ATTR-CM | Visit 1(baseline) through Follow-Up Visit 1 (Day 44) | ||
Secondary | Nt-proBNP results of HFpEF participants diagnosed with ATTR-CM compared with HFpEF participants negative for ATTR-CM | Visit 1(baseline) through Follow-Up Visit 1 (Day 44) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 |